Cyclopharm sets 8 May 2026 AGM and opens director nomination window

The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).

Cyclopharm Limited has scheduled its 2026 Annual General Meeting for 11:00 a.m. on 8 May 2026 at its boardroom in Kingsgrove, New South Wales. The company has also set 5:00 p.m. on 20 March 2026 as the deadline for shareholders to submit nominations for director elections at the meeting, signalling the start of its formal governance refresh and shareholder engagement process for the year.

The AGM timing and director nomination window provide shareholders with a defined period to influence the board’s composition and oversight of Cyclopharm’s expanding radiopharmaceutical operations. As the company continues to develop and apply its Technegas technology across a widening range of lung-related diseases, board elections at the upcoming meeting may shape its strategic direction and capital allocation priorities in a specialised and competitive medical imaging market.

The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed radiopharmaceutical company serving the global medical community with products for nuclear medicine and related clinicians. Its core product is Technegas, an ultra-fine radioactive carbon dispersion used for functional lung ventilation imaging, historically in pulmonary embolism diagnosis and increasingly in COPD, asthma, pulmonary hypertension and certain lung cancer and volume reduction surgeries.

Average Trading Volume: 90,965

Technical Sentiment Signal: Sell

Current Market Cap: A$88.05M

For an in-depth examination of CYC stock, go to TipRanks’ Overview page.